Leptospirosis Is Estimated To Witness High Growth Owing To Rising Incidences Of Disease

 

Leptospirosis Market

The global Leptospirosis Market is estimated to be valued at US$ 496.8 Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

 

Market Overview:

Leptospirosis is a zoonotic disease caused by pathogenic Leptospira interrogans bacteria. The disease affects both humans and animals through contact with urine of infected animals. The market offers vaccines, antibiotics and diagnostic tests to treat and prevent the disease. Effective vaccines are playing a key role in curbing the spread of the bacteria.

 

Market key trends:

One of the key trends fueling the market growth is rising adoption of vaccination programs globally, especially in regions with high disease prevalence. Growing awareness about the disease and availability of effective vaccines is encouraging governments as well as private organizations to invest in vaccination of at-risk population and livestock. Furthermore, initiatives by international organizations such as WHO to control and eliminate leptospirosis through global action plan are also boosting the market size. Lastly, improved diagnostics and continuous pipeline of innovative products are expected to drive further growth during the forecast period.

Segment Analysis

Leptospirosis market is segmented into drugs and diagnostics. Among these, drugs segment accounted for the largest market share in 2022 owing to rising awareness regarding leptospirosis treatment and increasing research and development activities for leptospirosis therapeutics. Diagnostics segment is expected to witness lucrative growth over the forecast period due to growing number of diagnostic tests available for accurate detection of leptospirosis.

 

Key Takeaways

The Global Leptospirosis Market Size is expected to witness high growth, exhibiting CAGR of 5.8% over the forecast period, 2023 to 2030, due to increasing incidence of leptospirosis worldwide.

 

Regional analysis

North America dominated the global Leptospirosis market in 2022 and is expected to remain dominant during the forecast period. This is attributed to favorable government initiatives towards spreading awareness about leptospirosis and presence of major players in the region. Asia Pacific is anticipated to witness lucrative growth over the coming years owing to rapid development of healthcare infrastructure and increasing prevalence of leptospirosis cases in the region.

 

Key players

Key players operating in the Leptospirosis market are USAntibiotics, Dr. Reddyâ€TMs Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical Industries, Inc., Ralington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd., and Aden Healthcare.

Read more

https://www.dailyprbulletin.com/leptospirosis-market-size-share-growth-outlook-2023

 

 

Comments

Popular posts from this blog

Uninterruptible Power Supply Market Poised for Significant Growth Accelerated by Adoption of Renewable Energy Sources

Yacht Charter Market is Estimated to Witness High Growth Owing to Opportunity of Increasing Recreational Boating

The Global Switchgear Market Growth Accelerated By Increased Demand For Switchgear From Renewable Energy Sector